|
Increased Minimization, Omission of Risk Info in Drug Promos, FDA Says
Drug and medical device companies are increasingly minimizing or omitting the risks associated with their products in advertising and promotional materials this year, an FDA official says. These violations have led to two warning letters and three untitled letters this year, Lisa Stockbridge, chief of CBER’s advertising and promotional labeling branch, said at the Drug Information Association’s annual meeting.
Washington Drug Letter |
Register Now
Archives